EP1128839A4 - Pharmazeutische zusammensetzungen enthaltend kopolymere synthetischer peptide und methoden zur vorbeugung und behandlung von gvhd und hvgd - Google Patents
Pharmazeutische zusammensetzungen enthaltend kopolymere synthetischer peptide und methoden zur vorbeugung und behandlung von gvhd und hvgdInfo
- Publication number
- EP1128839A4 EP1128839A4 EP99960378A EP99960378A EP1128839A4 EP 1128839 A4 EP1128839 A4 EP 1128839A4 EP 99960378 A EP99960378 A EP 99960378A EP 99960378 A EP99960378 A EP 99960378A EP 1128839 A4 EP1128839 A4 EP 1128839A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hvgd
- preventing
- methods
- pharmaceutical compositions
- synthetic peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10818498P | 1998-11-12 | 1998-11-12 | |
US108184P | 1998-11-12 | ||
US14521999P | 1999-07-23 | 1999-07-23 | |
US145219P | 1999-07-23 | ||
PCT/US1999/027107 WO2000027417A1 (en) | 1998-11-12 | 1999-11-12 | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1128839A1 EP1128839A1 (de) | 2001-09-05 |
EP1128839A4 true EP1128839A4 (de) | 2002-10-09 |
Family
ID=26805609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99960378A Withdrawn EP1128839A4 (de) | 1998-11-12 | 1999-11-12 | Pharmazeutische zusammensetzungen enthaltend kopolymere synthetischer peptide und methoden zur vorbeugung und behandlung von gvhd und hvgd |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1128839A4 (de) |
AU (1) | AU775073C (de) |
CA (1) | CA2355400A1 (de) |
WO (1) | WO2000027417A1 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
CA2337688C (en) | 1998-07-23 | 2016-04-05 | Yeda Research And Development Co., Ltd. | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
ES2349033T3 (es) | 2001-12-04 | 2010-12-22 | Teva Pharmaceutical Industries, Ltd. | Procedimientos para la medida de la actividad del acetato de glatiramer. |
NZ569331A (en) * | 2003-01-21 | 2010-08-27 | Yeda Res & Dev | COP 1 for treatment of inflammatory bowel diseases |
US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
BRPI0510738A (pt) | 2004-05-07 | 2007-11-20 | Peptimmune Inc | métodos de tratar doenças com copolìmeros aleatórios |
SI1797109T1 (sl) * | 2004-09-09 | 2016-07-29 | Yeda Research And Development Co., Ltd. | Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe |
ATE536363T1 (de) | 2004-09-09 | 2011-12-15 | Teva Pharma | Verfahren zur herstellung von mischungen von trifluoroacetyl-glatirameracetat bei verwendung von hydrobromsäure |
AU2005302500B2 (en) | 2004-10-29 | 2008-11-27 | Sandoz Ag | Processes for preparing glatiramer |
EP1843802A2 (de) * | 2005-01-31 | 2007-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mehrschichtiger polyelektrolytfilm, verfahren zur herstellung und verwendung |
AU2007238595A1 (en) | 2006-04-13 | 2007-10-25 | Peptimmune, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
BRPI0817682A2 (pt) | 2007-10-16 | 2015-04-07 | Peptimmune Inc | Métodos para projetar e preparar vacinas compreendendo composições de polímero de sequência direcionada via a expansão direta de epítopos |
CA2760802C (en) | 2009-08-20 | 2016-01-12 | Ety Klinger | Low frequency glatiramer acetate therapy |
US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
MX349162B (es) | 2010-01-04 | 2017-07-14 | Mapi Pharma Ltd * | Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo. |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
NZ703122A (en) | 2010-10-11 | 2016-06-24 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
WO2012143924A1 (en) | 2011-04-21 | 2012-10-26 | Mapi Pharma Ltd. | Random pentapolymer for treatment of autoimmune diseases |
WO2013055683A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
CA3050086A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992002543A1 (en) * | 1990-08-01 | 1992-02-20 | Cytel Corporation | Novel immunosuppressant peptides |
WO1994026774A1 (en) * | 1993-05-19 | 1994-11-24 | Cytel Corporation | Novel treatments for allergic diseases |
WO1995026980A2 (en) * | 1994-04-01 | 1995-10-12 | Immulogic Pharmaceutical Corporation | Haptenated peptides and uses thereof |
WO1995031997A1 (en) * | 1994-05-20 | 1995-11-30 | UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE ARMY | Model for testing immunogenicity of peptides |
WO1996032119A1 (en) * | 1995-04-14 | 1996-10-17 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of gvhd |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4339431A (en) * | 1980-12-31 | 1982-07-13 | Colgate-Palmolive Company | Anticalculus oral composition |
FR2658076B1 (fr) * | 1990-02-12 | 1992-06-12 | Sanofi Sa | Composition cosmetique contenant des copolymeres d'aminoacides, utile comme agent hydratant. |
-
1999
- 1999-11-12 CA CA002355400A patent/CA2355400A1/en not_active Abandoned
- 1999-11-12 WO PCT/US1999/027107 patent/WO2000027417A1/en active IP Right Grant
- 1999-11-12 AU AU17270/00A patent/AU775073C/en not_active Ceased
- 1999-11-12 EP EP99960378A patent/EP1128839A4/de not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992002543A1 (en) * | 1990-08-01 | 1992-02-20 | Cytel Corporation | Novel immunosuppressant peptides |
WO1994026774A1 (en) * | 1993-05-19 | 1994-11-24 | Cytel Corporation | Novel treatments for allergic diseases |
WO1995026980A2 (en) * | 1994-04-01 | 1995-10-12 | Immulogic Pharmaceutical Corporation | Haptenated peptides and uses thereof |
WO1995031997A1 (en) * | 1994-05-20 | 1995-11-30 | UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE ARMY | Model for testing immunogenicity of peptides |
WO1996032119A1 (en) * | 1995-04-14 | 1996-10-17 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of gvhd |
Non-Patent Citations (11)
Title |
---|
AHARONI RINA ET AL: "Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease.", IMMUNOLOGY LETTERS, vol. 58, no. 2, 1997, pages 79 - 87, XP002205821, ISSN: 0165-2478 * |
FRIDKIS-HARELI M. ET AL.: "Binding of random copolymers of three aminoacids to class II MHC molecules", INTERNATIONAL IMMUNOLOGY, vol. 11, no. 5, May 1999 (1999-05-01), pages 635 - 641, XP000893153 * |
FRIDKIS-HARELI M. ET AL.: "Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility comples molecules on living antigen-presenting cells - specificity and promiscuity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, 1994, WASHINGTON US, pages 4872 - 4876, XP000891508 * |
LI Q. ET AL.: "Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 342, 1998, pages 303 - 310, XP000893154 * |
SCHLEGEL P G ET AL: "A SYNTHETIC RANDOM BASIC COPOLYMER WITH PROMISCUOUS BINDING TO CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES INHIBITS T-CELLPROLIFERATIVE RESPONSES TO MAJOR AND MINOR HISTOCOMPATIBILITY ANTIGENS IN VITRO AND CONFERS THE CAPACITY TO PREVENT MURINE GRAFT-VERSUS-HOST DISEASE IN VIVO", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 10, 14 May 1996 (1996-05-14), pages 5061 - 5066, XP000578029, ISSN: 0027-8424 * |
See also references of WO0027417A1 * |
SELA M ET AL: "SUPPRESSIVE ACTIVITY OF COP-1 IN EAE AND ITS RELEVANCE TO MULTIPLE SCLEROSIS", BULL. INST. PASTEUR, vol. 88, 1990, pages 303 - 314, XP002926272 * |
TEITELBAUM D ET AL: "COPOLYMER 1 FROM THE LABORATORY TO FDA", ISRAEL JOURNAL OF MEDICAL SCIENCES, ISRAEL MEDICAL ASSOCIATION, TEL AVIV, IL, vol. 33, no. 4, April 1997 (1997-04-01), pages 280 - 284, XP002926268, ISSN: 0021-2180 * |
TEITELBAUM D ET AL: "CROSS-REACTIONS AND SPECIFICITIES OF MONOCLONAL ANTIBODIES AGAINST MYELIN BASIC PROTEIN AND AGAINST THE SYNTHETIC COPOLYMER1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 88, November 1991 (1991-11-01), pages 9528 - 9532, XP002949037, ISSN: 0027-8424 * |
TEITELBAUM D ET AL: "SUPPRESSION OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS BY A SYNTHETIC POLYPEPTIDE", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 1, 1971, pages 242,244,246,248, XP002926270, ISSN: 0014-2980 * |
TEITELBAUM D ET AL: "SYNTHETIC COPOLYMER 1 INHIBITS HUMAN T-CELL LINES SPECIFIC FOR MYELIN BASIC PROTEIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 89, January 1992 (1992-01-01), pages 137 - 141, XP002924839, ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
AU775073C (en) | 2007-05-03 |
CA2355400A1 (en) | 2000-05-18 |
EP1128839A1 (de) | 2001-09-05 |
AU775073B2 (en) | 2004-07-15 |
WO2000027417A1 (en) | 2000-05-18 |
AU1727000A (en) | 2000-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1128839A4 (de) | Pharmazeutische zusammensetzungen enthaltend kopolymere synthetischer peptide und methoden zur vorbeugung und behandlung von gvhd und hvgd | |
IL127545A0 (en) | Compositions and methods for administering borrelia DNA | |
PL343005A1 (en) | Pharmaceutical compositions for prolonged peptide release and preparation method | |
ZA974268B (en) | Ethylene copolymers and blend compositions | |
HUP9900935A3 (en) | Antifungic and antibacterial peptide and process for preparation | |
EP1025165A4 (de) | Verfahren und zusammensetzungen die polyphenol copolymer enthalten | |
IL138888A0 (en) | Pharmaceutical composition and combination preparation for immunosuppressive therapy | |
HUP0100082A3 (en) | Thrombin inhibitor, peptide derivatives, pharmaceutical compositions comprising thereof and their use | |
IL140742A0 (en) | Raloxifene and pharmaceutical composition comprising the same | |
IL125908A0 (en) | Peptides and pharmaceutical compositions comprising same | |
HUP0000460A3 (en) | Imidazopyridazines and pharmaceutical compositions thereof | |
IL125262A0 (en) | Synthetic peptides and pharmaceutical compositions comprising them | |
IL121329A (en) | Pharmaceutical composition for the treatment of cancer comprising somatostatin2 and other peptides | |
HUT74745A (en) | Pharmaceutical compositions containing p antagonist for treating pruritis, eye- and eyelid-acs and eye-and eyelid dysaesthesia | |
AU2001291994A1 (en) | Dipeptide ligands of the npff receptor for treating pain and hyperalgesia | |
EP0987942A4 (de) | Pharmazeutische zusammensetzung und verfahren zu ihrer verwendung | |
GB9606579D0 (en) | Pharmaceutical composition and methods for the manufacture thereof | |
GB9623962D0 (en) | Pharmaceutical composition | |
IL116976A0 (en) | Synthetic peptides and pharmaceutical compositions comprising them | |
IL137076A0 (en) | Bibapctitide-based pharmaceutical compositions for imaging and treating thrombi | |
EP0975610A4 (de) | Tripeptide und tetrapeptide als pharmazeutische verbindungen | |
ZA9811105B (en) | Cosmetic and pharmaceutical composition | |
HUP9600327A3 (en) | Pharmaceutical composition for treating or profilacting meteoropathy and different kinetoses | |
IL126009A0 (en) | Synthetic peptides and pharmaceutical compositions comprising them | |
GB9617346D0 (en) | Therapeutic methods and compositions for use therein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010612 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07K 5/00 A, 7C 07K 7/00 B, 7A 61K 38/00 B, 7C 07K 16/00 B, 7G 01N 33/53 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020823 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20050818 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: YEDA RESEARCH AND DEVELOPMEMT CO., LTD. |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: YEDA RESEARCH AND DEVELOPMENT CO., LTD. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20100427 |